Here are the 10-K annual reports from XBiotech Inc (XBIT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XBIT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIT filings page.
XBiotech Inc. filed an amended annual report to add detailed Part III disclosures on directors, executive compensation, ownership and equity plans for the year ended December 31, 2025. As of March 13, 2026, 30,487,731 common shares were outstanding and non‑affiliate equity had a market value of about $77.1 million as of June 30, 2025.
Former CEO John Simard received 2025 total compensation of about $30.1 million, including salary, bonuses, option awards and severance, while the median employee earned $87,096, resulting in a CEO pay ratio of roughly 345:1. The filing also describes board committee structures, director pay, and the transition from the expired 2015 equity plan to a new 2025 plan covering up to 8.38 million shares.
XBiotech Inc. filed its annual report describing a pre-market biopharmaceutical business focused on True Human monoclonal antibodies, particularly IL‑1α therapies for cancer, arthritis and stroke, plus an infectious disease pipeline. The company previously received $750 million from selling Bermekimab and has returned $495 million to shareholders via buybacks and dividends.
XBiotech recorded a net loss for 2025 and spent about $47.4 million on research and development, reflecting ongoing heavy investment without product revenue. As of March 13, 2026, 30,487,731 common shares were outstanding and the company employed 85 full‑time staff while emphasizing extensive clinical, regulatory, financing and commercialization risks.